Basic Calan Information

• INN (International Nonproprietary Name): Verapamil.
• Brand Names Available In United Kingdom: Generic Verapamil is marketed worldwide and Isoptin SR is listed for Europe; other brand names such as Calan, Calan SR, Verelan and Covera‑HS are noted in US listings but the UK market commonly supplies generic Verapamil or European branded equivalents.
• ATC Code: C08DA01.
• Forms & Dosages: Tablets 40 mg, 80 mg, 120 mg.
• Extended‑Release Tablets: 120 mg, 180 mg, 240 mg.
• Extended‑Release Capsules: 100 mg, 120 mg, 180 mg, 240 mg.
• Intravenous Solution (US Listing): 2.5 mg/mL (5 mg/2 mL ampoules).
• Manufacturers In United Kingdom: Global manufacturers include Abbott, Pfizer, Mylan, Teva and Sandoz, with local suppliers and marketing authorisations varying by product and supplier.
• Registration Status In United Kingdom: Verapamil is prescription‑only in most regions and is authorised in Europe; UK prescribers should follow MHRA and local formulary guidance.
• OTC / Rx Classification: Prescription‑only (Rx‑only).

Key Findings From Recent Trials

Major 2022–2024 Studies

Which trial results matter to my treatment choices?

Systematic reviews and large randomised controlled trials up to mid‑2024 show verapamil remains an effective option for acute rate control in supraventricular tachycardias and atrial arrhythmias.

Intravenous bolus regimens (commonly 5–10 mg IV, repeatable after about 30 minutes) produced rapid ventricular rate reduction in many acute care studies.

Oral extended‑release formulations demonstrated durable control of blood pressure and angina symptoms in longer trials and cohort analyses.

European and UK subgroup data reported in pooled analyses mirror global outcomes for rate control and angina relief.

These conclusions draw on aggregated evidence described in recent verapamil trials and verapamil clinical trials reviews spanning the 2022–2024 period.

Main Outcomes

What benefits can patients expect?

IV verapamil gives fast reduction of ventricular rate in atrial fibrillation/flutter and can terminate many cases of paroxysmal supraventricular tachycardia (PSVT) when used appropriately.

Oral ER verapamil reduced angina episode frequency and improved exercise tolerance compared with placebo in several meta‑analyses.

For hypertension, verapamil ER provides durable blood‑pressure reductions but is generally less favoured than dihydropyridine calcium‑channel blockers for first‑line treatment in UK primary care guidance.

Comparative data show verapamil’s negative inotropic action limits its role in systolic heart failure compared with amlodipine or ACE inhibitors for long‑term blood‑pressure management.

Safety Observations

What risks were seen in trials?

Across trials, common safety signals included bradycardia and varying degrees of AV block, particularly when verapamil was combined with other rate‑slowing drugs.

Meta‑analyses consistently reported increased constipation and higher rates of symptomatic bradycardia versus placebo.

Drug–drug interaction risks — notably with beta‑blockers and CYP3A4 substrates — were repeatedly emphasised as clinically important in safety analyses and trial reports.

Because of verapamil’s negative inotropic effects, several studies excluded patients with severe left ventricular dysfunction and noted worse outcomes where it was used inappropriately in such patients.

Clinical Mechanism Of Action

Layman’s Explanation

How does calan work in plain terms?

Verapamil slows the heartbeat and relaxes blood vessels by blocking calcium entry into heart and artery muscle cells.

That effect reduces the speed at which electrical signals pass through the heart’s AV node and lowers blood pressure and chest pain from angina.

Scientific Breakdown

What kind of calcium‑channel blocker is it?

Verapamil is a phenylalkylamine calcium‑channel blocker with ATC code C08DA01, showing greater selectivity for myocardial L‑type Ca2+ channels than dihydropyridine agents.

Its pharmacology explains the stronger effects on heart rate and conduction compared with vascular‑selective CCBs such as amlodipine.

Cardiac Electrophysiology

How does it change conduction?

Verapamil reduces inward calcium current during phases of the cardiac action potential that depend on L‑type channels, slowing AV nodal conduction and reducing sinus node automaticity.

That makes it particularly useful for supraventricular tachycardias and for acute control of atrial fibrillation or flutter where AV nodal slowing is desired.

Vascular Smooth Muscle Effects

How does it affect blood vessels and angina?

By producing vasodilation in arterial smooth muscle, verapamil lowers afterload and thereby reduces myocardial oxygen demand.

This mechanism underpins its role in chronic angina management and in blood‑pressure lowering when selected as part of therapy.

Immediate‑release tablets (40–120 mg) and extended‑release formulations (120–240 mg ER) change the absorption profile, with ER forms permitting once‑ or twice‑daily dosing for steady control.

Significant CYP3A4 metabolism provides a clear reason for vigilance about interactions with statins, macrolides and azole antifungals.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

When is verapamil licensed for use?

Approved indications include hypertension, angina pectoris (including variant angina), and supraventricular arrhythmias such as atrial fibrillation/flutter and PSVT.

In Europe the product appears as generic Verapamil and branded formulations such as Isoptin SR in some listings, and in the UK it remains prescription‑only.

Hospital formularies list both oral ER products and intravenous preparations for acute care use following trust protocols.

Notable Off‑Label Trends

Are doctors using calan for other things?

Specialist off‑label uses include targeted rate control for atrial fibrillation when beta‑blockers are unsuitable and as part of pre‑ablation strategies in selected patients.

Practical experimental uses have included limited specialist‑led trials in migraine/vascular headache protocols, but routine use for these indications is not established.

Pediatric use is specialist‑led and elderly prescribing typically starts lower with cautious titration.

Dosage Strategy

General Dosing

What are the common dose ranges?

Immediate‑release tablets commonly come in 40 mg, 80 mg and 120 mg strengths.

Extended‑release tablets and capsules are available in 100–240 mg presentations to allow once‑ or twice‑daily dosing depending on formulation.

For maintenance therapy in hypertension or angina, ER doses commonly fall in the 180–240 mg once‑ or twice‑daily range depending on clinical response.

Condition‑Specific Dosing

How should dosing be tailored to the condition?

Hypertension: Typical adult dosing is 80–120 mg three times daily with IR formulations or 180–240 mg once or twice daily with ER/SR products.

Angina: Dosing mirrors hypertension regimens, with many patients managed on IR 80–120 mg three times daily or the ER equivalent.

Acute Arrhythmias: Intravenous boluses of 5–10 mg IV (repeatable after ~30 minutes) are used for acute rate control or termination of PSVT where indicated by local acute‑care protocols.

Dose Adjustments: Start lower in elderly patients and in those with hepatic or renal impairment and titrate every 3–7 days while monitoring heart rate, blood pressure and ECG.

Paediatric dosing is specialist‑determined and should be guided by paediatric cardiology protocols when used.

Safety Protocols

Contraindications

Who must not take verapamil?

Absolute contraindications include severe hypotension (systolic blood pressure below 90 mmHg), sick sinus syndrome or second/third‑degree AV block without a pacemaker, severe left ventricular dysfunction or heart failure, cardiogenic shock and known hypersensitivity to verapamil or excipients.

Relative contraindications requiring careful monitoring include mild to moderate heart failure, hepatic or renal impairment, resting bradycardia below 50 bpm and concomitant negative inotropes such as beta‑blockers.

Adverse Effects

What side effects should patients expect?

Common effects include constipation, dizziness, headache, nausea and fatigue.

Dose‑related effects include bradycardia, peripheral oedema and flushing.

Serious reactions reported include AV block, pronounced hypotension, syncope and exacerbation of heart‑failure symptoms in susceptible patients.

Monitoring: Baseline ECG, blood pressure and heart rate are recommended before initiating therapy and after dose changes.

Overdose Management: Emergency supportive care is required for severe hypotension or bradycardia, with options including IV calcium, vasopressors and temporary pacing per resuscitation protocols.

Interaction Mapping

Food Interactions

Are there foods to avoid?

Grapefruit juice inhibits intestinal CYP3A4 and can increase verapamil plasma concentrations, so patients should be advised to avoid grapefruit while taking verapamil.

General dietary advice includes simple measures to reduce constipation, a common adverse effect with verapamil therapy.

Drug Combinations To Avoid

Which drugs cause major interactions?

Verapamil is a moderate CYP3A4 inhibitor and interacts with many drugs via metabolism and pharmacodynamic effects.

Clinically important interactions include increased digoxin levels and risk of digoxin toxicity, raised statin levels (for example simvastatin), and potentiation of beta‑blockers leading to profound bradycardia or AV block.

Co‑administration with other negative inotropes or antiarrhythmics needs specialist oversight and frequent monitoring.

Check the BNF and local formularies before combining verapamil with macrolide antibiotics, azole antifungals or potent CYP3A4 modulators.

Patient Experience Analysis

Survey Data

What do patients report in clinic audits?

Clinic surveys and patient questionnaires up to 2024 report good symptomatic control for angina and palpitations when verapamil is appropriately selected.

Recurring complaints that affect adherence include constipation and tiredness, particularly with sustained treatment.

Many patients prefer ER formulations for convenience and to reduce missed‑dose problems compared with multiple daily IR dosing.

Forum Trends

What do online patient communities say?

Common forum themes include concerns about dizziness on standing, worrying heart‑rate drops and questions about interactions with widely used medicines such as statins and antidepressants.

Real‑world adherence is sometimes challenged by side effects and by confusion between IR and ER formulations, so clear counselling and shared decision‑making improve persistence.

Patient advice should always include when to seek urgent care — syncope, chest pain or severe bradycardia require immediate assessment.

Distribution And Pricing Landscape

How easy is it to obtain calan in the UK?

Verapamil products are manufactured globally by companies such as Abbott, Pfizer, Mylan, Teva and Sandoz and supplied into UK channels either as generic Verapamil or as branded equivalents where available.

In the NHS supply chain generics typically have low per‑unit costs, while private prescription prices vary by brand and pack size.

Hospital formularies list IV preparations for acute care and ER oral formulations are widely present on primary‑care lists.

In our online pharmacy, calan is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Online pharmacies must follow MHRA requirements and registered wholesalers’ tender prices; check local procurement teams for current availability and shortage alerts.

Alternative Options

Comparison Table

• Amlodipine — A dihydropyridine CCB with robust antihypertensive efficacy and minimal negative inotropy; preferred for isolated systolic hypertension in older patients.
• Diltiazem — Shares AV‑nodal effects with verapamil but differs in tolerability for some patients and may be chosen if verapamil intolerance occurs.
• Nifedipine — Potent vasodilator useful in angina and hypertension; reflex tachycardia is a consideration.

Pros And Cons

How to choose between them?

Pros of verapamil include effective AV nodal blockade and established benefit in angina, with ER options enhancing adherence.

Cons include negative inotropy, a high rate of constipation, and extensive drug interactions via CYP3A4.

Choice depends on indication, comorbidities such as heart‑failure or bradycardia, and concurrent medications; for hypertension NICE guidance often prefers dihydropyridines while verapamil remains a specialist option for rhythm control and angina.

Regulatory Status

UK And EMA Position

What do regulators say?

Verapamil is prescription‑only in most jurisdictions and oral and IV formulations have approvals in the US and Europe, with ATC classification C08DA01.

In the UK and EU verapamil is authorised either as generic Verapamil or under branded names where applicable, and MHRA/EMA guidance and local formulary rules should be followed.

Adverse reactions should be reported to the UK Yellow Card scheme for pharmacovigilance.

Global Branding Notes

Which brand names might I see?

US brands include Calan, Calan SR, Verelan and Covera‑HS while European listings include Isoptin SR and various generics.

Marketing authorisations and packaging vary by country and language; for country‑specific licences consult the relevant national register.

Consolidated FAQ

Common Clinical Questions

Can verapamil be used first‑line for hypertension?

Not usually in UK primary care; dihydropyridine calcium‑channel blockers are generally preferred for first‑line hypertension treatment, while verapamil is used for specific indications such as angina or arrhythmia management.

Is grapefruit juice allowed?

No — grapefruit juice inhibits CYP3A4 and can increase verapamil levels and adverse effects.

What should a patient do if they miss a dose?

Take the missed dose when remembered unless it is near the time of the next dose; do not double up.

Can verapamil be combined with beta‑blockers?

Generally avoid or use extreme caution because the combination can cause severe bradycardia or AV block and requires close monitoring.

How should calan be stored?

Store at room temperature (15–30°C), protect from light and humidity, keep in original packaging and do not use past the expiry date.

Visual Guide

Suggested Infographics

Which visuals help both clinicians and patients?

Infographic 1 — Mechanism At A Glance: AV node blockade versus vascular smooth muscle effects, showing where verapamil acts on the heart and arteries.

Infographic 2 — Dosing Ladder: IR versus ER dose ranges with stepwise titration and monitoring checkpoints for BP and ECG.

Infographic 3 — Red Flags: When to stop verapamil and seek emergency care (syncope, chest pain, severe bradycardia) with clear action steps.

Include packaging visuals to distinguish IR (40/80/120 mg) from ER (120/180/240 mg) products and an IV ampoule depiction for acute care settings.

Storage And Transport

Pharmacy Handling

How should pharmacies store and manage stock?

Store oral products at room temperature (15–30°C) and protect from light and humidity.

Segregate IR and ER products and label packs clearly to avoid dispensing errors between sustained‑release and immediate‑release presentations.

IV ampoules for acute care should be stored according to trust pharmacy protocols and prepared immediately prior to use.

Patient Storage Guidance

What should patients be told?

Keep medication in the original packaging and out of reach of children, avoid storing in humid locations such as bathrooms and do not use beyond the expiry date.

Dispose of unused medicines through local NHS‑approved take‑back or disposal schemes.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers confirm before issuing a prescription?

Confirm the indication and check baseline ECG, blood pressure and heart rate.

Review current medications for interactions (statins, digoxin, beta‑blockers, CYP3A4 modulators) and assess hepatic and renal function.

Choose IR versus ER formulation based on adherence, comorbidity and the need for rapid titration, and start low in elderly patients.

Patient Counselling Points

What key points should patients hear at dispensing?

Explain constipation risk and simple dietary measures or laxative options if needed.

Advise to avoid grapefruit juice and to manage missed doses by taking them when remembered unless close to the next dose.

Instruct patients when to seek urgent help — severe dizziness, fainting, chest pain or very slow heart rate — and arrange appropriate follow‑up and ECG monitoring after initiation or dose changes.

Delivery Across United Kingdom

Frequently Asked Practical Points

How should pharmacies flag risks at point of sale?

Ensure medication records note baseline ECG findings, concurrent beta‑blocker or digoxin use and any history of heart‑failure or bradycardia.

Use clear labelling to indicate ER versus IR to reduce dosing errors and counsel patients on constipation prevention and interaction avoidance.

Final Prescribing Considerations

What final checks matter on the prescription?

Confirm the indication fits national guidance, check the patient’s full medication list for CYP3A4 and pharmacodynamic interactions and document the monitoring plan including when an ECG will be repeated.

For patients with significant LV dysfunction, prefer alternatives and consult cardiology if rhythm control is required.

Report suspected adverse reactions to the Yellow Card scheme to support ongoing pharmacovigilance in the UK.